C3AR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4987820	0.78	20/20
SCHEMBL4987829	0.78	20/20
SCHEMBL4995541	0.78	20/20
SCHEMBL4430935	0.77	20/20
SCHEMBL4425908	0.74	20/20
SCHEMBL4992987	0.70	20/20
SCHEMBL4993959	0.70	20/20
SCHEMBL4990322	0.68	20/20
SCHEMBL4989520	0.67	20/20
SCHEMBL4996254	0.65	20/20
SCHEMBL4991996	0.64	20/20
SCHEMBL4992256	0.62	20/20
SCHEMBL4994140	0.62	20/20
SCHEMBL4425958	0.61	20/20
SCHEMBL4990209	0.58	20/20
SCHEMBL4990199	0.56	20/20
SCHEMBL4989256	0.55	20/20
SCHEMBL4429465	0.50	20/20
SCHEMBL4986330	0.76	19/20
SCHEMBL4995868	0.66	19/20

Clinical trials — most relevant to C3AR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS	PHASE4	COMPLETED
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation	PHASE3	COMPLETED
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children	PHASE3	UNKNOWN
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis	PHASE3	COMPLETED
Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock	PHASE2/PHASE3	COMPLETED
Effect of Montelukast Versus Co Enzyme in Sepsis	PHASE2/PHASE3	COMPLETED
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis	PHASE2	COMPLETED
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)	PHASE2	COMPLETED
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.	PHASE2	COMPLETED
Defibrotide TMA Prophylaxis Pilot Trial	PHASE2	COMPLETED
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis	PHASE2	COMPLETED
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab	PHASE2	WITHDRAWN
Isolation of Cells From Biopsy Tissue to Aid in Kidney Repair	PHASE1	WITHDRAWN
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia	PHASE1	WITHDRAWN
Complement Activation in the Lysosomal Storage Disorders	nan	WITHDRAWN
Complement C5a Receptors in Hidradenitis Suppurativa	nan	COMPLETED
C5a Receptor Expression - COVID-19 (C5-COV)	nan	COMPLETED
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)	nan	RECRUITING
A Prospective Study of The Complement Depletion in Patients With Severe Abdominal Sepsis	nan	COMPLETED
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation	nan	COMPLETED
Effect of Platelet Storage on Complement Activation	nan	UNKNOWN
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome	nan	COMPLETED
Anesthetic Management and Remote Reperfusion Injuries	nan	COMPLETED
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia	nan	COMPLETED
Role of Renal Artery Doppler in Critically Ill Children With Acute Kidney Injury	nan	UNKNOWN
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy	nan	COMPLETED
Microparticles and the Risk of Re-stenosis Following Balloon Angioplasty in Patients With Peripheral Arterial Disease	nan	WITHDRAWN
DKK-3 rs11544814 and CFH rs10737680 Polymorphism and Protein Levels With Non Surgical Periodontal Therapy in Periodontitis Patients With and Without CAD	nan	UNKNOWN
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a C3AR1 binder may also engage these)

Protein	Name	Similarity
Q5REI5	—	1.000	Q5REI5 →
Q6TAC8	—	1.000	Q6TAC8 →
O88680	—	0.995	O88680 →
O09047	—	0.994	O09047 →
O55197	—	0.988	O55197 →
Q0VDU3	—	0.973	Q0VDU3 →
CCRL2	C-C chemokine receptor-like 2	0.972	landscape →
O35457	—	0.971	O35457 →
P70174	—	0.970	P70174 →
P43142	—	0.969	P43142 →
P15823	—	0.968	P15823 →
Q91175	—	0.968	Q91175 →
P97717	—	0.968	P97717 →
O60883	—	0.968	O60883 →
Q9QYC5	—	0.968	Q9QYC5 →
CCR2	C-C chemokine receptor type 2	0.968	landscape →
Q9Z0Z6	—	0.967	Q9Z0Z6 →
P25115	—	0.967	P25115 →
P31390	—	0.967	P31390 →
Q0II78	—	0.967	Q0II78 →
O18982	—	0.966	O18982 →
Q89609	—	0.966	Q89609 →
F5HF62	—	0.966	F5HF62 →
Q9N2B2	—	0.966	Q9N2B2 →
P35374	—	0.966	P35374 →
P54833	—	0.966	P54833 →
P51676	—	0.966	P51676 →
P46090	—	0.966	P46090 →
Q4KWL2	—	0.966	Q4KWL2 →
O97969	—	0.965	O97969 →